TUESDAY, FEBRUARY 28, 2017
6:15 PM - 9:00 PM
HYATT REGENCY ORLANDO HOTEL
9801 INTERNATIONAL DRIVE
ORLANDO, FL 32819
TARGET AUDIENCE
EDUCATIONAL OBJECTIVES
Upon completing this activity, the participant will be better able to:
- Describe current and emerging treatments for acute myeloid leukemia (AML)
- Identify diagnostic tests included in standard AML panels, and the role of cytogenetics & molecular analysis
- Utilize risk stratification for treatment planning
- Engage patients & caregivers in clinical trials discussions on emerging therapies for AML
- Apply strategies for optimal patient care
ADVISORY GROUP FACULTY
Jeffrey E. Lancet, MD (Chair) |
Jeffrey E. Lancet, MD (Chair) |
Wesam Ahmed, MD, PhD |
Julio Hajdenberg, MD, FACP |
Christopher R. Cogle, MD |
Maxim Norkin, MD, PhD |
Meera Iyengar, MD |
Kendra Sweet, MD, MS |
Daniel Landau, MD |
Chetasi Talati, MD |
Kendra Sweet, MD, MS |
Talia Zahra, MD |
Lauren Berger, MPH |
|
Seth Berkowitz, LCSW, CCLS |
|
Sharon Cohan, LCSW
|
This activity is supported by education grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Jazz Pharmaceuticals, Karyopharm Therapeutics, Inc. and Stemline Therapeutics, Inc.